Entero Therapeutics (ENTO) Competitors $2.04 +0.01 (+0.49%) Closing price 08/22/2025 04:00 PM EasternExtended Trading$2.04 +0.00 (+0.25%) As of 08/22/2025 07:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesInsider TradesSEC FilingsShort InterestTrendsBuy This Stock ENTO vs. FLGC, SNPX, GOVX, CSCI, LIXT, PHXM, IBIO, PHIO, HOOK, and IMCCShould you be buying Entero Therapeutics stock or one of its competitors? The main competitors of Entero Therapeutics include Flora Growth (FLGC), Synaptogenix (SNPX), GeoVax Labs (GOVX), COSCIENS Biopharma (CSCI), Lixte Biotechnology (LIXT), PHAXIAM Therapeutics (PHXM), iBio (IBIO), Phio Pharmaceuticals (PHIO), HOOKIPA Pharma (HOOK), and IM Cannabis (IMCC). These companies are all part of the "pharmaceutical products" industry. Entero Therapeutics vs. Its Competitors Flora Growth Synaptogenix GeoVax Labs COSCIENS Biopharma Lixte Biotechnology PHAXIAM Therapeutics iBio Phio Pharmaceuticals HOOKIPA Pharma IM Cannabis Entero Therapeutics (NASDAQ:ENTO) and Flora Growth (NASDAQ:FLGC) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, media sentiment, risk, dividends, profitability, analyst recommendations, institutional ownership and valuation. Is ENTO or FLGC more profitable? Entero Therapeutics has a net margin of 0.00% compared to Flora Growth's net margin of -24.86%. Flora Growth's return on equity of -261.57% beat Entero Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Entero TherapeuticsN/A -1,063.82% -17.94% Flora Growth -24.86%-261.57%-48.06% Do analysts rate ENTO or FLGC? Flora Growth has a consensus target price of $93.00, indicating a potential upside of 337.46%. Given Flora Growth's stronger consensus rating and higher probable upside, analysts clearly believe Flora Growth is more favorable than Entero Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Entero Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Flora Growth 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has higher earnings & valuation, ENTO or FLGC? Flora Growth has higher revenue and earnings than Entero Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioEntero TherapeuticsN/AN/A-$18.06MN/AN/AFlora Growth$59.51M0.21-$15.91M-$34.38-0.62 Do insiders & institutionals hold more shares of ENTO or FLGC? 12.3% of Entero Therapeutics shares are owned by institutional investors. Comparatively, 36.0% of Flora Growth shares are owned by institutional investors. 0.8% of Entero Therapeutics shares are owned by company insiders. Comparatively, 12.6% of Flora Growth shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. Which has more volatility & risk, ENTO or FLGC? Entero Therapeutics has a beta of 0.8, indicating that its share price is 20% less volatile than the S&P 500. Comparatively, Flora Growth has a beta of 1.97, indicating that its share price is 97% more volatile than the S&P 500. Does the media refer more to ENTO or FLGC? In the previous week, Entero Therapeutics had 2 more articles in the media than Flora Growth. MarketBeat recorded 3 mentions for Entero Therapeutics and 1 mentions for Flora Growth. Flora Growth's average media sentiment score of 0.91 beat Entero Therapeutics' score of -0.67 indicating that Flora Growth is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Entero Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Negative Flora Growth 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummaryFlora Growth beats Entero Therapeutics on 10 of the 13 factors compared between the two stocks. Get Entero Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ENTO and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ENTO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ENTO vs. The Competition Export to ExcelMetricEntero TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$3.22M$3.11B$5.76B$9.58BDividend YieldN/A2.23%4.41%4.10%P/E RatioN/A20.8831.1026.04Price / SalesN/A348.74435.03103.40Price / CashN/A43.1937.7358.48Price / Book-0.528.129.536.61Net Income-$18.06M-$54.72M$3.26B$265.56M7 Day Performance11.48%2.63%2.10%1.97%1 Month Performance35.73%2.78%2.82%-0.36%1 Year Performance65.09%11.01%30.56%19.03% Entero Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ENTOEntero TherapeuticsN/A$2.04+0.5%N/A+74.6%$3.22MN/A0.009FLGCFlora Growth3.318 of 5 stars$20.34+14.7%$93.00+357.2%-44.7%$11.80M$59.51M-0.59280High Trading VolumeSNPXSynaptogenixN/A$8.34+12.9%N/A+72.9%$11.59MN/A-0.834GOVXGeoVax Labs1.8713 of 5 stars$0.72+3.5%$8.88+1,127.0%-89.5%$11.52M$3.95M-0.3610Short Interest ↑Gap UpCSCICOSCIENS BiopharmaN/A$3.54-1.1%N/AN/A$11.36M$9.59M-0.6220Positive NewsLIXTLixte Biotechnology0.0498 of 5 stars$4.03-17.0%N/A+92.7%$10.92MN/A-3.164PHXMPHAXIAM TherapeuticsN/A$3.10flatN/AN/A$10.58MN/A0.0049IBIOiBio1.8894 of 5 stars$0.64+11.3%$5.00+683.7%-60.3%$10.54M$375K0.00100News CoverageGap DownPHIOPhio Pharmaceuticals2.9002 of 5 stars$2.19+2.1%$14.00+540.4%-31.7%$10.51MN/A-0.3410Analyst DowngradeGap UpHOOKHOOKIPA Pharma2.7866 of 5 stars$0.85+0.8%$4.50+428.2%-83.0%$10.39M$9.35M-0.15160IMCCIM Cannabis0.5112 of 5 stars$2.57-1.2%N/A-20.7%$10.38M$39.44M-4.02340 Related Companies and Tools Related Companies Flora Growth Competitors Synaptogenix Competitors GeoVax Labs Competitors COSCIENS Biopharma Competitors Lixte Biotechnology Competitors PHAXIAM Therapeutics Competitors iBio Competitors Phio Pharmaceuticals Competitors HOOKIPA Pharma Competitors IM Cannabis Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ENTO) was last updated on 8/23/2025 by MarketBeat.com Staff From Our PartnersBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Entero Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Entero Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access